Connecting via Winsock to STN

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1   Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches
         Zentralblatt
NEWS 3 OCT 19 BEILSTEIN updated with new compounds
NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 5 NOV 19 WPIX enhanced with XML display format
NEWS 6 NOV 30 ICSD reloaded with enhancements
NEWS 7 DEC 04 LINPADOCDB now available on STN
NEWS 8 DEC 14 BEILSTEIN pricing structure to change
NEWS 9 DEC 17 USPATOLD added to additional database clusters
NEWS 10 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 11 DEC 17 DGENE now includes more than 10 million sequences
NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in
         MEDLINE segment
NEWS 13 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14 DEC 17 CA/CAplus enhanced with new custom IPC display formats
NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content
         from USPATOLD
NEWS 16 JAN 02 STN pricing information for 2008 now available
NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified
         prophetic substances
NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
         custom IPC display formats
NEWS 19 JAN 28 MARPAT searching enhanced
NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days
         of publication
NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23 FEB 08 STN Express, Version 8.3, now available
NEWS 24 FEB 20 PCI now available as a replacement to DPCI

NEWS 25 FEB 25 IFIREF reloaded with enhancements
NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
          U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
      AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS LOGIN   Welcome Banner and News Items
NEWS IPC8   For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

 All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:47:24 ON 11 MAR 2008

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                               ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'CAPLUS' ENTERED AT 13:47:51 ON 11 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

```
=> s 1-8D or IFITM2
      9534696 1
       1443 8D
         37 1-8D
            (1(W)8D)
         39 IFITM2
L1      76 1-8D OR IFITM2

=> s L1 and (colon and (cancer or carcinoma or tumor or tumour or neoplasia or
malignancy)
UNMATCHED LEFT PARENTHESIS 'AND (COLON'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s L1 and (colon and (cancer or carcinoma or tumor or tumour or neoplasia or
malignancy))
       66065 COLON
         778 COLONS
        1710 COLA
          87 COLAS
       67949 COLON
            (COLON OR COLONS OR COLA OR COLAS)
      350758 CANCER
       51562 CANCERS
      363777 CANCER
            (CANCER OR CANCERS)
      177176 CARCINOMA
       34212 CARCINOMAS
         171 CARCINOMATA
      185424 CARCINOMA
            (CARCINOMA OR CARCINOMAS OR CARCINOMATA)
      443314 TUMOR
      166728 TUMORS
      494863 TUMOR
            (TUMOR OR TUMORS)
        3645 TUMOUR
        1377 TUMOURS
```

4935 TUMOUR
           (TUMOUR OR TUMOURS)
       15501 NEOPLASIA
       1538 NEOPLASIAS
       16662 NEOPLASIA
           (NEOPLASIA OR NEOPLASIAS)
       17751 MALIGNANCY
       18136 MALIGNANCIES
       33131 MALIGNANCY
           (MALIGNANCY OR MALIGNANCIES)
L2   8 L1 AND (COLON AND (CANCER OR CARCINOMA OR TUMOR OR
TUMOUR OR
       NEOPLASIA OR MALIGNANCY))

=> duplicate remove L2
PROCESSING COMPLETED FOR L2
L3   8 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

=> d L2 bib abs 1-8

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2007:1408247 CAPLUS
TI 1-8 interferon inducible gene family': putative colon
    carcinoma-associated antigens
AU   Tirosh, B.; Daniel-Carmi, V.; Carmon, L.; Paz, A.; Lugassy, G.; Vadai, E.;
    Machlenkin, A.; Bar-Haim, E.; Do, M.-S.; Ahn, I. S.; Fridkin, M.;
    Tzehoval, E.; Eisenbach, L.
CS   Department of Immunology, The Weizmann Institute of Science, Rehovot,
    Israel
SO   British Journal of Cancer (2007), 97(12), 1655-1663
    CODEN: BJCAAI; ISSN: 0007-0920
PB   Nature Publishing Group
DT   Journal
LA   English
AB   Db-/-x.beta.2 microglobulin (.beta.2m) null mice transgenic for a chimeric
    HLA-A2.1/Db-.beta.2m single chain (HHD mice) are an effective biol. tool
    to evaluate the antitumor cytotoxic T-lymphocyte response of known major
    histocompatibility-restricted peptide tumor-assocd. antigens,
    and to screen for putative unknown novel peptides. We utilized HHD
    lymphocytes to identify immunodominant epitopes of colon
    carcinoma overexpressed genes. We screened with HHD-derived
    lymphocytes over 500 HLA-A2.1-restricted peptides derived from
    colon carcinoma overexpressed genes. This procedure
    culminated in the identification of seven immunogenic peptides, three of
    these were derived from the human 1-8D gene from
    interferon inducible gene' (1-8D). The 1-

8D gene was shown to be overexpressed in fresh tumor
samples. The three 1-8D peptides were both antigenic
and immunogenic in the HHD mice. The peptides induce cytotoxic T
lymphocytes that were able to kill a colon carcinoma
cell line HCT/HHD, in vitro and retard its growth in vivo. One of the
peptides shared by all the 1-8 gene family primed efficiently normal human
cytotoxic T lymphocyte precursors. These results highlight the 1
-8D gene and its homologues as putative immunodominant
tumor-assocd. antigens of colon carcinoma.
British Journal of Cancer (2007) 97, 1655-1663.
doi:10.1038/sj.bjc.6604061 www.bjcancer.com Published online 11 Dec. 2007.

L2   ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2006:147678 CAPLUS
DN   144:206999
TI   Fragilis and Stella genes and proteins expressed in primordial germ cells
     and their uses as cell markers and for diagnosis and treatment of disease
IN   Saitou, Mitinori; Surani, Azim
PA   UK
SO   U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of Appl. No. PCT/GB03/03093.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
   PATENT NO.   KIND DATE   APPLICATION NO.   DATE
   --------------   ---- --------   -------------------   --------
PI US 2006035326   A1   20060216   US 2005-38876   20050118
   WO 2004007723   A2   20040122   WO 2003-GB3093   20030717
   WO 2004007723   A3   20040401
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
        CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
        GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
        LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
        PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
        TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
        KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
        FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
        BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2002-16727   A   20020717
   US 2002-397310P   P   20020719
   WO 2003-GB3093   A2   20030717
AB   The present invention relates to two primordial germ cell-specific
     expressed genes, Fragilis and Stella. The sequences and uses of human
     Stella and Fragilis are disclosed herein, as are several mouse sequences
     related to Fragilis. The present invention relates to the use of Stella

and Fragilis as markers for primordial germ cells and can be used to
identify such cells. Addnl., the present invention relates to the use of
Stella and Fragilis for the diagnosis, treatment, and/or prevention of
disease.

L2   ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2005:523621 CAPLUS
DN   143:54416
TI   DNA microarray for identifying genes regulated by basal transcription
     factors and biomarkers for treating diseases through regulation of
     hepatocyte nuclear factors
IN   Odom, Duncan T.; Young, Richard A.
PA   Whitehead Institute for Biomedical Research, USA
SO   PCT Int. Appl., 113 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.   KIND DATE   APPLICATION NO.   DATE
     --------------   ---- -------- ------------------- --------
PI   WO 2005054461   A2   20050616   WO 2004-US39805   20041123
     WO 2005054461   A3   20050909
       W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
          CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
          GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
          LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
          NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
          TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
       RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
          AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
          EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
          SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
          NE, SN, TD, TG
     US 2005239106   A1   20051027   US 2004-996240   20041123
     GB 2422837   A   20060809   GB 2006-10482   20041123
     DE 112004002318   T5   20070118   DE 2004-112004002318 20041123
     JP 2007515954   T   20070621   JP 2006-541476   20041123
PRAI US 2003-525318P   P   20031126
     US 2004-542520P   P   20040206
     US 2004-544835P   P   20040213
     US 2004-547933P   P   20040226
     WO 2004-US39805   W   20041123
AB   The invention relates to transcriptional regulators and related methods
     thereof. Detg. genes from a subset of genes that are regulated by a
     transcriptional regulator is achieved by (a) selectively isolating
     chromatin from a cell; (b) selectively isolating chromatin fragments which

are bound by the transcriptional regulator; (3) amplifying both the bound chromatin fragments and isolated chromatin to generate amplified chromatin fragments and amplified control chromatin, resp.; (4) hybridizing the amplified control and the amplified fragments to a DNA microarray; and (5) detg. and comparing a hybridization signal at each of the spots on the microarray between those generated by the amplified control chromatin and the amplified chromatin fragments. The DNA microarray for detg. promoter occupancy in a human cell, comprises (1) at least 10,000 expt. spots, each comprising a promoter region from a human gene; and (2) at least 100 control spots, each control spot comprising a non-promoter region. Applicants selected 15,000 cDNAs from the NCBI RefSeq database, mapped them to NCBI Build 22 of the human genome using BLAST, and amplified sequences from the genomic region -750 bp to +250 bp relative to the transcriptional start site. The invention also identifies genes regulated/occupied by the transcription factors HNF-1.alpha., HNF-4.alpha., and HNF-6 in human hepatocytes and pancreatic islets. Thus, the invention relates to the identification of genes regulated by transcriptional regulators, to the treatment of diseases assocd. with abnormal function of a transcriptional regulator, and to the modulation of gene expression, including genes expressed in hepatocytes or pancreatic cells, through the modulation of transcriptional regulator activity.

L2   ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2004:1081026 CAPLUS
DN   142:50129
TI   Microarray for determining expression of psychoneuroendocrinimmune genes
   and diagnosis of diseases
IN   Nicholson, Ainsley; Vernon, Suzanne D.
PA   The Government of the United States as Represented by the Secretary of the
   Department of Health and Human Services, USA
SO   PCT Int. Appl., 254 pp.
   CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
   PATENT NO.   KIND DATE   APPLICATION NO.   DATE
   --------------   ---- --------   -------------------   --------
PI WO 2004108899   A2   20041216   WO 2004-US17686   20040604
   WO 2004108899   A3   20070426
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
       CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
       GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
       LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
       NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
       TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

```
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG, AP, EA, EP, OA
    AU 2004245998      A1   20041216   AU 2004-245998      20040604
    CA 2528162         A1   20041216   CA 2004-2528162     20040604
    IN 2006DN00084     A    20070824   IN 2006-DN84        20060104
PRAI US 2003-475915P    P    20030604
    WO 2004-US17686     W   20040604
AB   Disclosed are compns. and methods for microarrays comprising genes
```

involved in psychoneuroendocrinimmune (PNI) activity. An oligonucleotide
microarray composed entirely of PNI genes was designed, which can allow a
researcher to assess the overall psychoneuroendocrineimmune state of an
individual, and to observe systemic responses to various stresses. The
PNI array has widespread applicability and marketability in the diagnosis
and treatment of diseases that result from dysregulation of the
hypothalamic-pituitary-adrenal axis. A total of 1451 genes encoding 1738
transcriptional products can be distinguished and samples from human or
mouse can hybridize with equal affinity, facilitating animal studies.
Arabidopsis and housekeeping genes are used as controls. To det. the
extent of peripheral blood PNI gene expression, both EST and microarray
databases were queried; there were 566 genes from an EST database that
matched to one of 1622 genes in the PNI database. The utility of the PNI
array is demonstrated for research of chronic fatigue syndrome and other
diseases involving PNI.

```
L2   ANSWER 5 OF 8  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2004:162713 CAPLUS
DN   140:198079
TI   Vaccines comprising human tumor-associated antigen encoded by
     1-8D interferon-induced gene for treating colon
     or prostate cancer
IN   Eisenbach, Lea; Tirosh, Boaz; Carmon, Lior; Machlenkin, Arthur; Paz,
     Adrian; Tzehoval, Esther; Fridkin, Matityahu
PA   Yeda Research and Development Co. Ltd., Israel; Mcinnis, Patricia
SO   PCT Int. Appl., 134 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
    PATENT NO.       KIND  DATE      APPLICATION NO.     DATE
    --------------   ----  --------  -------------------  --------
PI  WO 2004016643     A2   20040226  WO 2003-US23503     20030728
    WO 2004016643     A3   20050630
       W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
```

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
        LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
        PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
        TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
        KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
        FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
        BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
   AU 2003256912   A1   20040303   AU 2003-256912   20030728
   EP 1569514   A2   20050907   EP 2003-788282   20030728
     R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
   US 2006263342   A1   20061123   US 2005-524787   20050923
PRAI US 2002-403657P   P   20020816
   WO 2003-US23503   W   20030728
AB The invention relates to colon and prostate tumor
   assocd. antigen peptides obtainable from prostate specific G
   protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of
   prostate (STEAP) and proteins encoded by genes found overexpressed in
   colon carcinoma cells, such as human 1-
   8D interferon induced transmembrane protein 2. The invention
   further relates to a polynucleotide encoding the tumor assocd.
   antigen peptides and to pharmaceutical compns., which are preferably anti-
   tumor vaccine compns., contg. a tumor assocd. antigen,
   at least one tumor assocd. antigen peptide thereof, or encoding
   polynucleotide thereof as an active ingredient. The pharmaceutical
   compns. can be administered to a patient in need thereof to treat or
   inhibit the development of colon or prostate cancer.

L2 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:60672 CAPLUS
DN 140:123717
TI Protein and nucleotide sequences of human and mouse Fragilis and Stella
   genes expressed in primordial germ cell and its therapeutic uses
IN Saitou, Mitinori; Surani, Azim
PA Cambridge University Technical Services Limited, UK
SO PCT Int. Appl., 192 pp.
   CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2
   PATENT NO.   KIND DATE   APPLICATION NO.   DATE
   -------------   ---- -------- ------------------- --------
PI WO 2004007723   A2   20040122 WO 2003-GB3093   20030717
   WO 2004007723   A3   20040401
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
     CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
     GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
     LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
     PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
     TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
   RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
     KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
     FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
     BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2493675      A1   20040122   CA 2003-2493675      20030717
AU 2003255720     A1   20040202   AU 2003-255720      20030717
EP 1521832      A2   20050413   EP 2003-764023      20030717
   R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
     IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005532808     T   20051104   JP 2004-520898      20030717
US 2006035326     A1   20060216   US 2005-38676      20050118
PRAI GB 2002-16727     A   20020717
   US 2002-397310P    P   20020719
   WO 2003-GB3093     W   20030717
AB  We described two primordial germ cell-specifically expressed genes,
   Fragilis and Stella. The sequences and uses of human Stella and Fragilis
   are disclosed, as well as several related mouse sequences related to
   Fragilis. Stella and Fragilis which are markers for primordial germ cells
   and may be used to identify such cells in cell populations. They may also
   be used for diagnosing, treating and/or preventing diseases such as
   cancers.


L2  ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN  2004:3065 CAPLUS
DN  140:72104
TI  Method for diagnosis of colorectal tumors and pre-malignant
   lesions by the scoring of gene expression profiles, and antitumor drug
   screening using the same
IN  Nakamura, Yusuke; Furukawa, Yoichi
PA  Oncotherapy Science, Inc., Japan; Japan as Represented by the President of
   the University of Tokyo
SO  PCT Int. Appl., 80 pp.
   CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
   PATENT NO.      KIND  DATE     APPLICATION NO.      DATE
   --------------   ----  --------   -------------------   --------
PI  WO 2004001072     A2   20031231   WO 2002-JP12760     20021205
   WO 2004001072     A3   20050407
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
```

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499709   A1   20031231   CA 2002-2499709   20021205
AU 2002349786   A1   20040106   AU 2002-349786   20021205
JP 2005529625   T   20051006   JP 2004-515468   20021205
US 2006199179   A1   20060907   US 2004-518938   20041217
PRAI US 2002-389994P   P   20020619
WO 2002-JP12760   W   20021205
AB The invention provides objective methods for detecting and diagnosing
colorectal cancers and pre-malignant lesions. For example, the
methods disclosed herein can reliably detect very early-stage colorectal
cancers. In one embodiment, the diagnostic method involves the
scoring of gene expression profiles that discriminate between adenomas and
carcinomas. The profile score calcd. acts as diagnostic indicator
that can objectively indicate whether a sample tissue is non-cancerous,
pre-cancerous, or cancerous. The present invention further provides
methods of diagnosing colorectal tumors in a subject, methods of
screening for therapeutic agents useful in the treatment of colorectal
tumors, methods of treating colorectal tumors and method
of vaccinating a subject against colorectal tumors.

L2 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:354356 CAPLUS
DN 135:120439
TI Alterations of gene expression during colorectal carcinogenesis revealed
by cDNA microarrays after laser-capture microdissection of tumor
tissues and normal epithelia
AU Kitahara, Osamu; Furukawa, Yoichi; Tanaka, Toshihiro; Kihara, Chikashi;
Ono, Kenji; Yanagawa, Renpei; Nita, Marcelo E.; Takagi, Toshihisa;
Nakamura, Yusuke; Tsunoda, Tatsuhiko
CS Human Genome Center, Institute of Medical Science, The University of
Tokyo, Tokyo, 108-8639, Japan
SO Cancer Research (2001), 61(9), 3544-3549
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB To identify a set of genes involved in the development of colorectal
carcinogenesis, we compared expression profiles of colorectal

cancer cells from eight tumors with corresponding noncancerous colonic epithelia using a DNA microarray consisting of 9216 human genes. These cell populations had been rendered homogeneous by laser-capture microdissection. Expression change in more than half of the tumors was obsd. for 235 genes, i.e., 44 up-regulated and 191 down-regulated genes. The differentially expressed genes include those assocd. with signal transduction, metabolizing enzymes, prodn. of reactive oxygen species, cell cycle, transcription, mitosis, and apoptosis. Subsequent examn. of 10 genes (five up-regulated and five down-regulated) by semiquant. reverse transcription-PCR using the eight tumors together with an addnl. 12 samples substantiated the reliability of our anal. The extensive list of genes identified in these expts. provides a large body of potentially valuable information of colorectal carcinogenesis and represents a source of novel targets for cancer therapy.

RE.CNT 32   THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT